echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Ann Intern Med: Influence of frailty on the efficacy and safety of dapagliflozin in heart failure patients with reduced ejection fraction

    Ann Intern Med: Influence of frailty on the efficacy and safety of dapagliflozin in heart failure patients with reduced ejection fraction

    • Last Update: 2022-05-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Frailty may alter the risk-benefit profile of some treatments, and frail patients may have reduced tolerance to treatment
    .
    Recently, a research article was published in Annals of Internal Medicine, an authoritative journal of internal medicine.
    The study aimed to explore the role of dapagliflozin in DAPA-HF (dapagliflozin
    prevention of heart failure) using the Rockwood cumulative loss method according to the patient's frail status.
    efficacy in adverse exhaustion outcomes)

    .

    prevention

    The study is a post hoc analysis of a phase 3 randomized clinical trial conducted at 410 sites in 20 countries (ClinicalTrials.
    gov: NCT03036124)

    .
    Patients were symptomatic heart failure (HF) patients with a left ventricular ejection fraction of 40% or less and elevated natriuretic peptides

    .
    The intervention in the study was the addition of 10 mg of dapagliflozin or placebo once daily to the
    guideline
    -recommended treatment .
    The outcome of the study was worsening of
    heart failure or cardiovascular death .

    Guidelines for Heart Failure Vascular

    Frailty index (FI) was calculated in 4742 of the 4744 randomly assigned DAPA-HF patients
    .
    A total of 2392 (50.
    4%) patients had FI grade 1 (FI≤0.
    210; not frail), 1606 (33.
    9%) patients had FI grade 2 (FI 0.
    211-0.
    310); 744 (15.
    7%) patients had FI Grade 3 (FI≥0.
    311; the most vulnerable)

    .
    The median follow-up time was 18.
    2 months

    .
    Dapagliflozin reduced the risk of HF worsening or cardiovascular death, regardless of FI class

    .
    The difference in event rates per 100 person-years between the dapagliflozin and placebo groups from the lowest FI grade to the highest FI grade was -3.
    5 (95% CI -5.
    7 to -1.
    2), -3.
    6 (CI -6.
    6) to -0.
    5) and -7.
    9 (CI of -13.
    9 to -1.
    9)

    .
    Consistent benefits were observed across other clinical events and health conditions, but absolute reductions were generally greater in the most frail patients

    .
    Study drug discontinuations and serious adverse events were no more frequent with dapagliflozin than with placebo, regardless of FI class

    .

    CONCLUSIONS: Dapagliflozin improved outcomes across all assessments, regardless of the patient's frail status
    .
    However, absolute reductions were greater in weaker patients

    .

    CONCLUSIONS: Dapagliflozin improved outcomes across all assessments, regardless of the patient's frail status
    .
    However, absolute reductions were greater in weaker patients

    .

    Original source:

    Original source:

    Jawad H.
    Butt, et al.
    Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction A Post Hoc Analysis of the DAPA-HF Trial .
    Ann Intern Med 2022.
    https:// /10.
    7326/M21-4776

    Jawad H.
    Butt, et al.
    Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction A Post Hoc Analysis of the DAPA-HF Trial .
    Ann Intern Med 2022.
    https:// /10.
    7326/M21-4776
    Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction A Post Hoc Analysis of the DAPA-HF

    Trial
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.